查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1511921

美国生物防御市场规模、份额和趋势分析报告：按产品和细分市场预测，2024-2030 年

U.S. Biodefense Market Size, Share & Trends Analysis Report By Product (Anthrax, Small Pox, Botulism, Radiation/nuclear), And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 80 Pages | 商品交期: 2-10个工作天内

价格

美国生物防御市场的成长与趋势：

Grand View Research, Inc.最新报告显示，到2030年，美国生物防御市场预计将达到179亿美元，2024年至2030年复合年增长率为4.1%。

美国生物防御市场受到政府资金增加、全球健康问题、技术进步、监管要求、合作和准备需求以及经济奖励等因素的推动。这些因素确保提供有效的生物防御解决方案，保护人们免受潜在的生物威胁，并为产业的成长和发展做出贡献。美国生物防御市场受益于基因组学、生物资讯学和合成生物学等技术的快速进步。这些创新能够快速识别病原体、开发标靶治疗并改善诊断。

2022 年 9 月，国防部 (DoD) 计划投资 10 亿美元加强国内生物工业製造基础设施，让美国创新者更容​​易获得这些基础设施，特别是在商业和国防供应方面，旨在刺激私营和公共部门扩张。此外，国防部将额外拨款2亿美元，用于加强这些设施的生物安全和网路安全措施。同时，美国农业部 (USDA) 承诺拨款 5 亿美元，利用生物技术和生物製造领域的进步来津贴美国农民，促进独立、创新和永续的美国化肥生产。推出。

美国生物防御市场报告亮点

  • 由于其高致死率、易于製造、稳定性、大规模杀灭潜力以及持续改进现有治疗方法和疫苗的需要，到 2023 年，炭疽菌将占产品份额的 28.1%。
  • 预计辐射/核武产业在预测期内将以显着的复合年增长率成长。
  • 生物恐怖主义感染疾病的增加以及新出现的感染疾病的可能性正在促进美国生物防御市场的成长。
  • 2022 年 1 月，Integrated Viral Protection LLC (IVP) 推出了一款可携式空气过滤设备，可以一次清除多种空气传播的病毒，包括 COVID-19 和炭疽菌孢子。

目录

第一章调查方法和范围

第 2 章执行摘要

第三章美国生物防御市场变数、趋势与范围

  • 市场体系展望
    • 母市场展望
    • 相关/附随市场展望
  • 市场动态
    • 市场推动要素分析
    • 市场限制因素分析
  • 美国生物防御市场分析工具
    • 产业分析-波特五力分析
    • PESTEL分析

第四章美国生物防御市场：产品估算与趋势分析

  • 2023年及2030年产品市场占有率
  • 细分仪表板
  • 美国生物防御市场展望：依产品分类
  • 2018-2030年市场规模、预测及趋势分析

第五章竞争状况

  • 主要市场参与企业的最新趋势和影响分析
  • 公司/竞争对手分类
  • 供应商情况
  • 公司简介
    • XOMA Corporation
    • Altimmune, Inc.
    • EMERGENT
    • Dynavax Technologies
    • SIGA Technologies
    • Elusys Therapeutics, Inc.
    • Ichor Medical Systems
    • Dynport Vaccine Company（General Dynamics Information Technology, Inc.）
    • Cleveland Biolabs
    • Bavarian Nordic
    • Ology Bioservices, Inc.
    • Alnylam Pharmaceuticals, Inc.
Product Code: GVR-4-68040-313-4

U.S. Biodefense Market Growth & Trends:

The U.S. biodefense market is anticipated to reach USD 17.90 billion by 2030, and is expected to grow at a CAGR of 4.1% from 2024 to 2030, according to a new report by Grand View Research, Inc. The U.S. biodefense market is driven by factors such as increased government funding, global health concerns, technological advancements, regulatory requirements, the need for collaboration and preparedness, and economic incentives. These drivers contribute to the growth and development of the industry, ensuring that effective biodefense solutions are available to protect populations from potential biological threats. The U.S. biodefense market benefits from rapid advancements in technology, such as genomics, bioinformatics, and synthetic biology. These innovations enable faster identification of pathogens, development of targeted therapies, and improved diagnostics.

In September 2022, the Department of Defense (DoD) planned to invest USD 1 billion to boost domestic bio-industrial manufacturing infrastructure, facilitating accessibility for U.S. innovators, which aimed at incentivizing private and public sectors to expand manufacturing capacities, particularly for critical chemicals vital to commercial and defense supply chains. In addition, the DoD was expected to allocate an extra USD 200 million to enhance biosecurity and cybersecurity measures for these facilities. Collectively, the U.S. Department of Agriculture (USDA) was expected to introduce a USD 500 million grant program in summer 2022 to foster independent, innovative, and sustainable American fertilizer production, leveraging advancements in biotechnology and biomanufacturing to support domestic farmers.

U.S. Biodefense Market Report Highlights:

  • Anthrax dominated the product segment with 28.1% share in 2023 owing to its high lethality, ease of production, stability, potential for mass casualties, and the ongoing need to improve existing treatments and vaccines.
  • The radiation/nuclear segment is expected to grow at a significant CAGR over the forecast period.
  • The increasing incidents of bioterrorism, the potential for new and emerging infectious diseases are contributing to the growth of the U.S. biodefense market.
  • In January 2022, Integrated Viral Protection LLC (IVP) launched a portable air filtration device capable of eliminating a wide range of airborne viruses, including COVID-19 and anthrax spores, in a single pass, boasting exceptional efficacy with patented biodefense technology.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Product
    • 1.2.2. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Volume price analysis (Model 2)
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Product outlook
  • 2.3. Competitive Insights

Chapter 3. U.S. Biodefense Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
    • 3.2.2. Market restraint analysis
  • 3.3. U.S. Biodefense Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape

Chapter 4. U.S. Biodefense Market: Product Estimates & Trend Analysis

  • 4.1. Product Market Share, 2023 & 2030
  • 4.2. Segment Dashboard
  • 4.3. U.S. Biodefense Market by Product Outlook
  • 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the Following
    • 4.4.1. Anthrax
      • 4.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
    • 4.4.2. Smallpox
      • 4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
    • 4.4.3. Botulism
      • 4.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
    • 4.4.4. Radiation/nuclear
      • 4.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
    • 4.4.5. Others
      • 4.4.5.1. Market estimates and forecasts 2018 to 2030 (USD Billion)

Chapter 5. Competitive Landscape

  • 5.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 5.2. Company/Competition Categorization
  • 5.3. Vendor Landscape
    • 5.3.1. List of key distributors and channel partners
    • 5.3.2. Key customers
    • 5.3.3. Key company heat map analysis, 2023
  • 5.4. Company Profiles
    • 5.4.1. XOMA Corporation
      • 5.4.1.1. Company overview
      • 5.4.1.2. Financial performance
      • 5.4.1.3. Product benchmarking
      • 5.4.1.4. Strategic initiatives
    • 5.4.2. Altimmune, Inc.
      • 5.4.2.1. Company overview
      • 5.4.2.2. Financial performance
      • 5.4.2.3. Product benchmarking
      • 5.4.2.4. Strategic initiatives
    • 5.4.3. EMERGENT
      • 5.4.3.1. Company overview
      • 5.4.3.2. Financial performance
      • 5.4.3.3. Product benchmarking
      • 5.4.3.4. Strategic initiatives
    • 5.4.4. Dynavax Technologies
      • 5.4.4.1. Company overview
      • 5.4.4.2. Financial performance
      • 5.4.4.3. Product benchmarking
      • 5.4.4.4. Strategic initiatives
    • 5.4.5. SIGA Technologies
      • 5.4.5.1. Company overview
      • 5.4.5.2. Financial performance
      • 5.4.5.3. Product benchmarking
      • 5.4.5.4. Strategic initiatives
    • 5.4.6. Elusys Therapeutics, Inc.
      • 5.4.6.1. Company overview
      • 5.4.6.2. Financial performance
      • 5.4.6.3. Product benchmarking
      • 5.4.6.4. Strategic initiatives
    • 5.4.7. Ichor Medical Systems
      • 5.4.7.1. Company overview
      • 5.4.7.2. Financial performance
      • 5.4.7.3. Product benchmarking
      • 5.4.7.4. Strategic initiatives
    • 5.4.8. Dynport Vaccine Company (General Dynamics Information Technology, Inc.)
      • 5.4.8.1. Company overview
      • 5.4.8.2. Financial performance
      • 5.4.8.3. Product benchmarking
      • 5.4.8.4. Strategic initiatives
    • 5.4.9. Cleveland Biolabs
      • 5.4.9.1. Company overview
      • 5.4.9.2. Financial performance
      • 5.4.9.3. Product benchmarking
      • 5.4.9.4. Strategic initiatives
    • 5.4.10. Bavarian Nordic
      • 5.4.10.1. Company overview
      • 5.4.10.2. Financial performance
      • 5.4.10.3. Product benchmarking
      • 5.4.10.4. Strategic initiatives
    • 5.4.11. Ology Bioservices, Inc.
      • 5.4.11.1. Company overview
      • 5.4.11.2. Financial performance
      • 5.4.11.3. Product benchmarking
      • 5.4.11.4. Strategic initiatives
    • 5.4.12. Alnylam Pharmaceuticals, Inc.
      • 5.4.12.1. Company overview
      • 5.4.12.2. Financial performance
      • 5.4.12.3. Product benchmarking
      • 5.4.12.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviations
  • Table 2 U.S. biodefense market, by product, 2018 - 2030 (USD Billion)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value-chain-based sizing & forecasting
  • Fig. 6 QFD modeling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 U.S. biodefense market: market outlook
  • Fig. 9 Biodefense competitive insights
  • Fig. 10 Parent market outlook
  • Fig. 11 Related/ancillary market outlook
  • Fig. 12 Penetration and growth prospect mapping
  • Fig. 13 U.S. biodefense market driver impact
  • Fig. 14 U.S. biodefense market restraint impact
  • Fig. 15 U.S. biodefense market: Product movement analysis
  • Fig. 16 U.S. biodefense market: Product outlook and key takeaways
  • Fig. 17 Anthrax market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 18 Smallpox estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 19 Botulism market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 20 Radiation/nuclear estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 21 Others estimates and forecasts, 2018 - 2030 (USD Billion)